DAS-181 is under clinical development by Ansun Biopharma and currently in Phase I for Enterovirus Infections. According to GlobalData, Phase I drugs for Enterovirus Infections have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DAS-181’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

DAS-181 overview

DAS-181 is under development for the treatment of influenza A virus,H1N1 and H3N2 subtype, influenzavirus B,enterovirus, beta corona virus infections including COVID-19 infections, metapneumovirus and lower respiratory tract infection due to parainfluenza type 3 virus infections in immunocompromized patients. The drug candidate is a nebulized drug formulation which is administered inhalationally as a dry powder. It is a recombinant fusion protein consisting of a sialidase catalytic domain (derived from Actinomyces viscosus sialidase) and an epithelial surface-anchoring heparin-binding domain derived from the human protein amphiregulin. It was also under development for asthma, pandemic influenza and bronchiectasis.

Ansun Biopharma overview

Ansun Biopharma is a biopharmaceutical company which develops biologic therapeutics to treat unmet medical needs and respiratory infections. The company’s product pipeline includes DAS181, a sialidase enzyme being developed to treat parainfluenza, influenza, metapneumovirus and Enterovirus68, a cause of mild infectious illnesses. It also develops solutions to cure pandemic flu strains. The company is funded by 3E Bioventures, Lilly Asia Ventures, Lyfe Capital, VI Ventures and others. Ansun Biopharma is headquartered in San Diego, California, the US.

For a complete picture of DAS-181’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.